MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Metrics to compare | MDWD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDWDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.7x | 11.6x | −0.5x | |
PEG Ratio | −0.29 | 0.15 | 0.00 | |
Price/Book | 4.8x | 1.0x | 2.6x | |
Price / LTM Sales | 12.3x | 2.1x | 3.2x | |
Upside (Analyst Target) | 84.4% | 178.8% | 45.2% | |
Fair Value Upside | Unlock | 28.6% | 6.4% | Unlock |